Cresset Asset Management, LLC Immuno Gen, Inc. Transaction History

Cresset Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $305,689 - $536,749	-71,758 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$4.75 - $7.5 $151,002 - $238,425	31,790 Added 79.54%	71,758 $533,000
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $91,820 - $120,537	18,291 Added 84.38%	39,968 $226,000
Q2 2021 Aug 10, 2021	BUY	$5.79 - $8.6 $12,187 - $18,103	2,105 Added 10.76%	21,677 $143,000
Q1 2021 May 12, 2021	BUY	$6.5 - $10.53 $36,822 - $59,652	5,665 Added 40.73%	19,572 $158,000
Q4 2020 Feb 11, 2021	BUY	$3.7 - $7.66 $51,455 - $106,527	13,907 New	13,907 $90,000
Q2 2019 Aug 12, 2019	SELL	$1.8 - $3.3 $1,805 - $3,309	-1,003 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $1,067 - $2,618	443 Added 79.11%	1,003 $3,000
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $2,206 - $5,432	560 New	560 $269,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.